SXLV:LSE:LSE-SPDR S&P U.S. Health Care Select Sector UCITS (USD)

ETF | Others |

Last Closing

USD 43.525

Change

+0.11 (+0.25)%

Market Cap

USD 0.38B

Volume

2.32K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

+1.50 (+0.82%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-0.06 (-0.05%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.17 (+1.21%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.20 (+1.11%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.35 (-0.50%)

USD 266.08B
0QZO:LSE 0QZO

+0.25 (+0.27%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.32 (+1.02%)

USD 208.06B
0QZ3:LSE Qualcomm Inc.

+1.69 (+1.01%)

USD 202.26B
0R24:LSE Intel Corp.

+0.22 (+0.99%)

USD 196.14B

ETFs Containing SXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.11% 56% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.11% 55% F 58% F
Trailing 12 Months  
Capital Gain 12.72% 53% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.72% 52% F 57% F
Trailing 5 Years  
Capital Gain 64.61% 81% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.61% 79% B- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.42% 74% C 75% C
Dividend Return 11.42% 74% C 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.57% 63% D 77% C+
Risk Adjusted Return 107.97% 98% N/A 99% N/A
Market Capitalization 0.38B 65% D 49% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike